These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 28482147

  • 1. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
    Twarda-Clapa A, Krzanik S, Kubica K, Guzik K, Labuzek B, Neochoritis CG, Khoury K, Kowalska K, Czub M, Dubin G, Dömling A, Skalniak L, Holak TA.
    J Med Chem; 2017 May 25; 60(10):4234-4244. PubMed ID: 28482147
    [Abstract] [Full Text] [Related]

  • 2. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
    Surmiak E, Twarda-Clapa A, Zak KM, Musielak B, Tomala MD, Kubica K, Grudnik P, Madej M, Jablonski M, Potempa J, Kalinowska-Tluscik J, Dömling A, Dubin G, Holak TA.
    ACS Chem Biol; 2016 Dec 16; 11(12):3310-3318. PubMed ID: 27709883
    [Abstract] [Full Text] [Related]

  • 3. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
    Vaupel A, Bold G, De Pover A, Stachyra-Valat T, Lisztwan JH, Kallen J, Masuya K, Furet P.
    Bioorg Med Chem Lett; 2014 May 01; 24(9):2110-4. PubMed ID: 24704029
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.
    Jacob AG, Singh RK, Comiskey DF, Rouhier MF, Mohammad F, Bebee TW, Chandler DS.
    PLoS One; 2014 May 01; 9(8):e104444. PubMed ID: 25105592
    [Abstract] [Full Text] [Related]

  • 6. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
    Grace CR, Ban D, Min J, Mayasundari A, Min L, Finch KE, Griffiths L, Bharatham N, Bashford D, Kiplin Guy R, Dyer MA, Kriwacki RW.
    J Mol Biol; 2016 Mar 27; 428(6):1290-1303. PubMed ID: 26812210
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, To KH, Linn M, Podlaski F, Wovkulich P, Vu B, Vassilev LT.
    Cancer Res; 2013 Apr 15; 73(8):2587-97. PubMed ID: 23400593
    [Abstract] [Full Text] [Related]

  • 11. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
    Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J.
    J Biol Chem; 2006 Nov 03; 281(44):33030-5. PubMed ID: 16905541
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
    Barakat K, Mane J, Friesen D, Tuszynski J.
    J Mol Graph Model; 2010 Feb 26; 28(6):555-68. PubMed ID: 20056466
    [Abstract] [Full Text] [Related]

  • 18. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
    Chen R, Zhou J, Qin L, Chen Y, Huang Y, Liu H, Su Z.
    Biochemistry; 2017 Jun 27; 56(25):3273-3282. PubMed ID: 28581721
    [Abstract] [Full Text] [Related]

  • 19. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A, Leão M, Soares J, Palmeira A, Pinto M, Saraiva L, Sousa ME.
    Med Res Rev; 2016 Sep 27; 36(5):789-844. PubMed ID: 27302609
    [Abstract] [Full Text] [Related]

  • 20. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S, Loureiro JB, Inga A, Reis F, Gomes C, Santos MMM, Saraiva L.
    Mol Oncol; 2017 Jun 27; 11(6):612-627. PubMed ID: 28296148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.